You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-pan-AKT (phospho T308) antibody (ab38449)

CodeSizePriceAbpointsAvailability
    
 
  • -

  •   
  •   
  •   
  •  

  •  
  •  
  •  

  •  
Updating...

Reassurance, Refunds & Replacements

If your product does not perform as described on this datasheet, we will refund or replace your product...

Read our guarantee »

Overview

Product name

Anti-pan-AKT (phospho T308) antibody
See all pan-AKT products (6) ...

Description

Rabbit polyclonal to pan-AKT (phospho T308)

Specificity

ab38449 recognises endogenous levels of AKT (pT308), AKT2 (pT309) and AKT3 (pT305) only when phosphorylated at those residues.

Tested applications

WB, ELISA, IHC-Pmore details

Cross reactivity

Reacts with

Mouse, Rat, Human

Immunogen

Synthetic phosphopeptide derived from human AKT1 around the phosphorylation site of Threonine 308 (MKTpFC).

Positive control

Human lung carcinoma, extracts from 293 cells.

Properties

Form

Liquid

Storage instructions

Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid freeze / thaw cycles.

Storage buffer

Preservative: 0.02% Sodium Azide
Constituents: 50% Glycerol, PBS, 150mM Sodium chloride, pH 7.4

Concentration

Concentration information loading...

Purity

Immunogen affinity purified

Clonality

Polyclonal

Isotype

IgG

  • Western blot - AKT1 (phospho T308) antibody (ab38449)Western blot - AKT1 (phospho T308) antibody (ab38449) image (enlarge)

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-pan-AKT (phospho T308) antibody (ab38449)Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-pan-AKT (phospho T308) antibody (ab38449) image (enlarge)

Applications

Show applications key

Our Abpromise guarantee covers the use of ab38449 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • ShowHide1 Image

    WB

     WB: 1/500 - 1/1000. Pred...Read more →

    WB: 1/500 - 1/1000. Predicted molecular weight: 56 kDa.

  • ELISA

     ELISA: 1/10000.

    ELISA: 1/10000.

  • 1 Image

    IHC-P

     IHC-P: 1/50 - 1/100.

    IHC-P: 1/50 - 1/100.

Target

Function

Plays a role as a key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). General protein kinase capable of phosphorylating several known proteins. Phosphorylates TBC1D4. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor I (IGF-I). Plays a role in glucose transport by mediating insulin-induced translocation of the GLUT4 glucose transporter to the cell surface. Mediates the antiapoptotic effects of IGF-I. Mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. Promotes glycogen synthesis by mediating the insulin-induced activation of glycogen synthase. The activated form can suppress FoxO gene transcription and promote cell cycle progression. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly.

Tissue specificity

Expressed in all human cell types so far analyzed. The Tyr-176 phosphorylated form shows a significant increase in expression in breast cancers during the progressive stages i.e. normal to hyperplasia (ADH), ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC) and lymph node metastatic (LNMM) stages.

Involvement in disease

Defects in AKT1 are a cause of susceptibility to breast cancer (BC) [MIM:114480]. A common malignancy originating from breast epithelial tissue. Breast neoplasms can be distinguished by their histologic pattern. Invasive ductal carcinoma is by far the most common type. Breast cancer is etiologically and genetically heterogeneous. Important genetic factors have been indicated by familial occurrence and bilateral involvement. Mutations at more than one locus can be involved in different families or even in the same case.
Defects in AKT1 are associated with colorectal cancer (CRC) [MIM:114500].
Defects in AKT1 are associated with susceptibility to ovarian cancer [MIM:604370]; also called susceptibility to familial breast-ovarian cancer type 1 (BROVCA1).

Sequence similarities

Belongs to the protein kinase superfamily. AGC Ser/Thr protein kinase family. RAC subfamily.
Contains 1 AGC-kinase C-terminal domain.
Contains 1 PH domain.
Contains 1 protein kinase domain.

Domain

Binding of the PH domain to the phosphatidylinositol 3-kinase alpha (PI(3)K) results in its targeting to the plasma membrane. The PH domain mediates interaction with TNK2 and Tyr-176 is also essential for this interaction.
The AGC-kinase C-terminal mediates interaction with THEM4.

Post-translational
modifications

Phosphorylation on Thr-308, Ser-473 and Tyr-474 is required for full activity. Activated TNK2 phosphorylates it on Tyr-176 resulting in its binding to the anionic plasma membrane phospholipid PA. This phosphorylated form localizes to the cell membrane, where it is targeted by PDPK1 and PDPK2 for further phosphorylations on Thr-308 and Ser-473 leading to its activation. Ser-473 phosphorylation by mTORC2 favors Thr-308 phosphorylation by PDPK1. Ser-473 phosphorylation is enhanced by interaction with AGAP2 isoform 2 (PIKE-A). Ser-473 phosphorylation is enhanced in focal cortical dysplasias with Taylor-type balloon cells.
Ubiquitinated; undergoes both 'Lys-48'- and 'Lys-63'-linked polyubiquitination. TRAF6-induced 'Lys-63'-linked AKT1 ubiquitination is critical for phosphorylation and activation. When ubiquitinated, it translocates to the plasma membrane, where it becomes phosphorylated. When fully phosphorylated and translocated into the nucleus, undergoes 'Lys-48'-polyubiquitination catalyzed by TTC3, leading to its degradation by the proteasome.

Cellular localization

Cytoplasm. Nucleus. Cell membrane. Nucleus after activation by integrin-linked protein kinase 1 (ILK1). Nuclear translocation is enhanced by interaction with TCL1A. Phosphorylation on Tyr-176 by TNK2 results in its localization to the cell membrane where it is targeted for further phosphorylations on Thr-308 and Ser-473 leading to its activation and the activated form translocates to the nucleus.

Target information above from: UniProt accessionP31749 The UniProt Consortium
The Universal Protein Resource (UniProt) in 2010
Nucleic Acids Res. 38:D142-D148 (2010).

Information by UniProt

Alternative names

  • AKT1 antibody
  • AKT1_HUMAN antibody
  • AKT2 antibody
  • AKT3 antibody
  • MGC9965 antibody
  • Oncogene AKT1 antibody
  • PKB alpha antibody
  • PKB antibody
  • PKB beta antibody
  • PKBalpha antibody
  • PRKBA antibody
  • PRKBB antibody
  • PRKBG antibody
  • Protein kinase B antibody
  • Protein kinase B beta antibody
  • Protein kinase B gamma antibody
  • Proto-oncogene c-Akt antibody
  • RAC alpha antibody
  • RAC antibody
  • RAC gamma antibody
  • RAC PK alpha antibody
  • RAC PK beta antibody
  • RAC PK gamma antibody
  • RAC-alpha serine/threonine-protein kinase antibody
  • RAC-PK-alpha antibody
  • STK2 antibody
see all

Anti-pan-AKT (phospho T308) antibody images:

  Western blot - AKT1 (phospho T308) antibody (ab38449)

Western blot - AKT1 (phospho T308) antibody (ab38449)

All lanes : Anti-pan-AKT (phospho T308) antibody (ab38449) at 1/500 dilution

Lane 1 : The extracts from 293 cells untreated
Lane 2 : The extracts from 293 cells treated with insulin.

Lysates/proteins at 30 µg per lane.


Predicted band size : 56 kDa
Observed band size : 56 kDa


Lanes can be loaded with 5-30µg of total protein.

  Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-pan-AKT (phospho T308) antibody (ab38449)

Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) - Anti-pan-AKT (phospho T308) antibody (ab38449)

Immunohistochemical analysis of AKT (phospho T308) expression in paraffin embedded human lung carcinoma tissue, using ab38449 (1/50). Right-hand panel represents a negative control where ab38449 was pre-incubated with the immunizing (blocking) peptide.

References for Anti-pan-AKT (phospho T308) antibody (ab38449)

This product has been referenced in:

See all 5 publications for this product

Publishing research using ab38449? Please let us know so that we can cite the reference in this datasheet

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"